Therapeutics

Discover how dropless cataract surgery enhances patient comfort and outcomes, reducing the need for eye drops and improving recovery efficiency.

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

Chinese researchers reveal that low-level red light therapy may control myopia in children but raises concerns about retinal damage and cone density reduction.

ENTOD Pharmaceuticals launches Myatro XL, a 0.05% atropine eye drop, to effectively slow myopia progression in children, available by prescription in 2025.

Personalizing treatment options and setting realistic expectations are crucial.

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx

The recent agreement with Cipla adds to the list of partnerships Formosa has formed for APP13007.

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s second, approved IGF-1R antibody drug.

The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary antibody biopolymer conjugate (ABC) platform.

Clinician highlights a novel complication of atropine treatment in a teenage patient.

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria.

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

Alice T. Epitropoulos, MD, FACS, outlines her approach to managing evaporative dry eye. This includes diagnosing meibomian gland dysfunction, using thermal pulsation to clear gland blockages, and ensuring long-term results with advanced treatments and patient education.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 inhibitor therapy.

Electrical stimulation therapy is being explored as a potential treatment to enhance neuroplasticity and improve visual function in optic neuropathy patients. Clinical trials show promising results in visual field improvements, though further research is needed on long-term efficacy and quality of life.

According to Iridex Corp., the study confirms MicroPulse TLT's sustained safety and efficacy in managing glaucoma, reducing intraocular pressure and medication reliance with minimal complications over 5 years.

In an interview with Ophthalmology Times, clinical trial investigator Zaina Al-Mohtaseb MD, noted the CLARA Phase 1/2 trial demonstrated the safety, efficacy, and simplicity of corneal endothelial cell injection therapy with a rho kinase inhibitor, offering a less invasive alternative to traditional corneal transplantation for treating corneal edema.

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.